Cytek Biosciences Q3 revenue rises 2% on US growth
CTKB•Cytek Biosciences’ third-quarter revenue rose 2% year over year to $53.23 million, while gross margin improved nearly 600 basis points. It maintained the midpoint of its 2026 revenue guidance and narrowed the range to $208 million-$211 million.
1. Quarterly results
Cytek Biosciences reported third-quarter revenue of $53.23 million, up 2% year over year and slightly above the $52.80 million consensus estimate. The company reported a net loss of $6.10 million and adjusted EBITDA of $711,000.
2. Revenue and outlook
Revenue growth was led by the U.S. market, with strong demand for high-end instruments and continued growth in service. Recurring revenue from service and reagents increased as a share of total revenue, and gross margin improved nearly 600 basis points on a better product and service mix. Cytek expects 2026 revenue of $208 million to $211 million, maintaining the midpoint of its previous guidance, and expects a strong finish to the year and continued market share gains.
